50% offfirst month · 3+ month plans
Patient portalFind my treatment
Rebody PT-141 nasal spray bottle on a clean background
All treatments

Rebody treatment guide

PT-141 Nasal Spray Strengths: 5 mg/mL and 10 mg/mL

Choose nasal PT-141 for a compact administration step, not because a larger concentration number guarantees a better result.

Choose PT-141 nasal spray when administration speed matters, not because 10 mg/mL looks more powerful than 5 mg/mL. Both products come in refrigerated 5 mL bottles. The prescribed dose cannot be known until pump output, amount per spray, and sprays per use are confirmed.

The short answer

The two bottles contain bremelanotide at different concentrations: 5 mg/mL and 10 mg/mL. A higher concentration places more active in each milliliter. It does not establish more desire, faster onset, longer duration, or better tolerability.

The nasal format wins for someone who wants a compact as-needed object without injection or oral dissolve time. The 5 mg/mL concentration is not available in California; current state availability appears during the online visit.

Nasal options at a glance

Product fact 5 mg/mL 10 mg/mL
Active Bremelanotide Bremelanotide
Bottle 5 mL 5 mL
Storage Refrigerated Refrigerated
Metered output See dispensing label See dispensing label
Sprays per prescribed use Patient-specific Patient-specific
State availability Not available in California Confirm during the online visit

Each 5 mL bottle is $99.50 first month, then $199. Days of supply, actuation count, and refill cadence remain prescription-specific.

Concentration is not dose

Milligrams per milliliter tells you how much active is present in a volume. The actual dose depends on how many milliliters one actuation dispenses and how many actuations are prescribed.

A 10 mg/mL bottle could deliver the same prescribed amount with a different actuation plan than a 5 mg/mL bottle. Without metered volume, any dose chart would be arithmetic built on a missing fact.

Do not halve sprays, double sprays, or switch concentrations by mental conversion. A new concentration needs its own written directions.

What the small nasal studies show

A double-blind crossover experiment gave one 20 mg intranasal dose to 18 premenopausal women with female sexual arousal disorder. Researchers evaluated physiological and subjective arousal measures.

Another early program studied intranasal PT-141 in healthy men and men with mild-to-moderate ED, examining pharmacology, tolerability, and erectile response.

These studies show that intranasal bremelanotide has been investigated in people. They do not establish Rebody's pump output, concentration choice, prescribed dose, onset, or outcomes.

What the approved evidence cannot prove here

Vyleesi is a 1.75 mg subcutaneous bremelanotide injection approved for acquired, generalized HSDD in premenopausal women. Its pivotal 24-week trials measured desire and distress.

The injection label cannot be converted to a nasal dose. Subcutaneous and intranasal routes have different exposure, timing, formulation, and package behavior.

Use Vyleesi to explain bremelanotide's approved population and active-level safety questions. Do not call a compounded nasal spray FDA-approved or clinically equivalent.

Choosing 5 mg/mL versus 10 mg/mL

Choose the exact product prescribed after final pump specifications and state availability are known. Do not make 10 mg/mL the default winner. Higher concentration can reduce volume for a given amount, but it can also change local exposure and dosing error consequences.

The 5 mg/mL presentation is not available in California, which can remove it from the decision entirely. Geography is a product fact, not a reason to imply the remaining bottle is clinically superior.

The two concentrations are distinct products. The most useful comparison is the final drug delivered per actuation once that measurement appears on the finished label.

Priming and first use

A metered nasal pump may need priming before first use or after a period without use. The number of presses, whether to spray into air, and when to reprime depend on the exact dispenser.

Use only the priming instructions supplied with this bottle. Overpriming can waste medication and make the bottle run out early.

The dispensing instructions cover cap removal, bottle orientation, nostril placement, inhalation, and cleaning.

Nostril technique and congestion

The approved SIG must state whether sprays alternate nostrils and what to do when more than one actuation is used. Aim and inhalation can change throat runoff and local irritation.

Congestion, a cold, nosebleed, recent nasal procedure, or damaged mucosa can affect comfort and delivery. Do not compensate with extra sprays.

If liquid repeatedly runs down the throat or out of the nose, check technique and dispenser function rather than assuming the dose failed.

Timing and duration

Search results are full of exact onset and multi-hour duration claims. The Rebody bottles do not have route-specific final guidance establishing those numbers.

The approved injection is used at least 45 minutes before anticipated activity, but that is not a nasal instruction. The 20 mg women's nasal experiment and early men's studies used study-specific timing.

Use the prescribed lead time when approved. Do not redose because an internet countdown passed without a felt effect.

Leaking, blocked, or early-empty bottles

Keep the cap on and bottle upright when instructed. A leaking pump, cracked bottle, blocked actuator, irregular mist, or visible damage can change delivered volume.

Do not poke the nozzle with a pin, add liquid, or move medication into another spray bottle. Record the issue and remaining supply.

An early empty bottle may reflect overpriming, leakage, excess sprays, or a mistaken actuation count. Resolve the cause before refill.

Refrigeration and travel

Both concentrations are refrigerated. Keep the original labeled bottle protected from freezing and direct ice-pack contact. Ask how long the final formula can remain out of refrigeration.

For travel, use a leak-resistant secondary pouch and keep the cap in place. Do not decant. Airline and security questions are easier when the prescription label remains visible.

If a shipment arrives warm, report timing and package condition. Coldness, clarity, or color alone cannot determine stability.

Side effects and urgent symptoms

The Vyleesi label's common and serious questions include nausea, flushing, headache, vomiting, injection-site reactions, transient blood-pressure increase, reduced heart rate, focal hyperpigmentation, and delayed gastric emptying. Injection-site reactions obviously do not describe nasal use.

Nasal route can add local irritation, congestion, unpleasant taste, runoff, or nosebleed questions. Product-specific rates are not established for these bottles.

Uncontrolled hypertension and known cardiovascular disease are contraindications on the approved injection label. Seek urgent care for chest pain, fainting, severe allergic symptoms, concerning blood-pressure symptoms, or prolonged painful erection.

Interactions and maximum use

The Vyleesi label warns that delayed gastric emptying can affect oral medication absorption and that bremelanotide can reduce systemic exposure to oral naltrexone. These are active-level questions that deserve attention.

The injection limit of one dose in 24 hours and eight doses per month is not a nasal-spray instruction. Use the frequency printed on the nasal prescription.

Alcohol, sildenafil, tadalafil, antihypertensives, and other sexual-health treatments require product-specific guidance rather than a public stack recipe.

Price, doses per bottle, and refills

Each PT-141 nasal strength is $99.50 first month, then $199 per 5 mL bottle. A 5 mL bottle cannot be priced per dose until metered volume, prescribed sprays, priming waste, actuation count, and billable days of supply are known.

Before starting, confirm concentration, amount per spray, expected prescribed uses per bottle, storage, package price, and refill timing. Those facts change the purchase.

The customer price is $99.50 first month, then $199 per bottle. The bottle is not automatically a one-month supply because prescribed use varies.

Questions people ask

Is 10 mg/mL stronger than 5 mg/mL?

It is more concentrated. The delivered dose still depends on pump output and prescribed sprays.

How many sprays should be used?

Use the number printed on the prescription label. Concentration and bottle volume alone are not enough to answer.

Does nasal PT-141 work for women?

A small 18-woman intranasal experiment exists, but it did not test these finished bottles or establish an approved indication.

Does it work for men?

Small early intranasal studies included men. Vyleesi is not approved for male ED, and the evidence is much thinner than for PDE5 inhibitors.

Can the bottle travel unrefrigerated?

Use the final temperature and excursion instructions. Do not assume a universal time.

Bottom line

PT-141 nasal spray is the quickest physical route in Rebody's bremelanotide family. The choice between 5 mg/mL and 10 mg/mL belongs to the metered dose, state availability, and prescription—not a bigger-number preference. Both are available at $99.50 first month, then $199 per 5 mL bottle; follow the product-specific directions for sprays per use.

Keep exploring PT-141

Primary sources